Lineage Cell Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1990-01-01
- Employees
- 75
- Market Cap
- $171.3M
- Website
- http://www.lineagecell.com
36-Month Results of OpRegen Cell Therapy for Geographic Atrophy to Be Presented at CTS 2025
Long-term 36-month data from the Phase 1/2a trial of RG6501 (OpRegen) for geographic atrophy secondary to AMD will be presented at Clinical Trials at the Summit in June 2025.
Lineage Cell Therapeutics Launches DOSED Study for Novel Spinal Cord Injury Cell Therapy
Lineage Cell Therapeutics has initiated the DOSED clinical study to evaluate OPC1, a stem cell-derived therapy, using a new delivery system for both subacute and chronic spinal cord injury patients.
Emerging Therapies Offer Hope for Geographic Atrophy Treatment
Several therapies are under evaluation in clinical trials for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), addressing the unmet need for effective treatments.
RG6501 Shows Rapid Improvement in Retinal Structure for Geographic Atrophy Patients
Phase 1/2a trial results for RG6501 (OpRegen) demonstrate significant improvements in outer retinal structure within three months of a single administration in patients with geographic atrophy secondary to AMD.